Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07207369
PHASE3

A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars

Sponsor: AbbVie

View on ClinicalTrials.gov

Summary

Atrophic acne scars are flat, indented or with an inverted center scars that develop at the endpoint of the normal healing process for acne. Acne scarring that remains after acne resolves has a significant impact on health related quality of life, including reduced self-esteem and embarrassment/self consciousness. ELAPR002f provides an immediate space-occupying effect for filling in the scar tissue. The purpose of this study is to assess how safe and effective ELAPR002f injectable gel is on adult participants with atrophic acne scars. ELAPR002f injectable gel is an investigational device being developed for the treatment of facial atrophic acne scars. There are 2 cohorts in this study. In Cohort 1, all participants will receive ELAPR002f injectable gel. In Cohort 2, participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to the saline active control group. Around 395 adult participants with moderate to severe atrophic acne scarring on both cheeks will be screened in the study in approximately 25 sites in the United States. Participants will receive 3 treatments over 2 months of intradermal injections of either ELAPR002f injectable gel or saline active control and will be followed for up to an additional 12 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Official title: A Multicenter, Cohort-design, Double-blind, Randomized, Parallel-group, Controlled Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars

Key Details

Gender

All

Age Range

22 Years - Any

Study Type

INTERVENTIONAL

Enrollment

395

Start Date

2025-10-24

Completion Date

2029-11

Last Updated

2025-11-24

Healthy Volunteers

No

Conditions

Interventions

DEVICE

ELAPR002f Injectable Gel

Intradermal Injections

DEVICE

Saline Control

Intradermal Injections

Locations (10)

Advanced Research Associates - Glendale /ID# 254961

Glendale, Arizona, United States

Marcus Facial Plastic Surgery /ID# 275880

Redondo Beach, California, United States

Pacific Clinical Innovations /ID# 256185

Vista, California, United States

DMR Research PLLC /ID# 256199

Westport, Connecticut, United States

Hamilton Research, LLC /ID# 256925

Alpharetta, Georgia, United States

Aesthetic Center at Woodholme /ID# 256197

Baltimore, Maryland, United States

The Center for Dermatology Cosmetics & Laser Surgery /ID# 256182

Mount Kisco, New York, United States

Wilmington Dermatology Center /ID# 256192

Wilmington, North Carolina, United States

Austin Institute for Clinical Research - Pflugerville /ID# 256200

Pflugerville, Texas, United States

SkinDC /ID# 254962

Arlington, Virginia, United States